Jin Rong Jie·2025-11-27 06:06Core Viewpoint - Rongchang Biologics (09995) experienced a significant stock increase, rising over 7% in the afternoon trading session, with a current price of 90.75 HKD and a trading volume of 319 million HKD, indicating strong market interest and potential investor confidence [1]. Group 1: Clinical Research and Product Development - At the 2025 ESMO annual meeting, clinical research results were published showing that Vidisicimab combined with Toripalimab outperformed chemotherapy as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma [1]. - Yongxing Securities reported that the combination therapy of Vidisicimab demonstrates excellent efficacy, marking a significant change in the treatment landscape for urothelial carcinoma [1]. - CITIC Construction Investment noted that in 2025, the core product Taitasip will rapidly expand after receiving approval for new indications, and the data for the combination treatment with Vidisicimab is promising [1]. Group 2: Pipeline and Market Position - The application for the DME indication of RC28 has been accepted, indicating progress in the company's pipeline [1]. - Among the pipeline products, RC148 has received breakthrough therapy designation, with continuous validation of its clinical data [1]. - Overall, the company is accelerating its commercialization process and has a well-structured pipeline, suggesting a positive outlook for future development [1].